United States of America
Mr. McKinney began his career at Du Pont Merck with roles in hospital sales, market research and new product planning. He was part of the core team that launched Ethmozine, a class 1 anti-arrhythmic. He spent six years at Texas Biotechnology where he was closely involved in the development and approval of argatroban, a direct thrombin inhibitor. In 2000 Mr. McKinney was a member of the start-up executive team at Novazyme, a biotech involved in lysosomal storage disorders and which was subsequently acquired by Genzyme. At Genzyme he took on a Sr. VP and General Manager role and helped guide the integration of the Novazyme and Genzyme early phase research programs. In 2004 Mr. McKinney began at Orexigen and in early 2005 became the Chief Operating Officer with involvement in all aspects of corporate fund raising including series B and C rounds, successful Initial Public Offering and follow-on secondary offering. He had primary oversight of a substantial IP portfolio resulting in 7 major patent allowances/issuances and was the co-inventor of several important patents underlying Contrave and Empatic formulations. Mr. McKinney also had direct responsibility of formulation development and manufacturing operations, Business Development, Corporate Communications, Reimbursement and Pricing Strategy and Biostatistics. Mr. McKinney holds a Bachelor of Science in Microbiology (concentration in chemistry) from the University of Oklahoma and an M.B.A. in Global Management from the Thunderbird School of Global Management.
Euthymics is a neuroscience-focused, clinical-stage biopharmaceutical company. Euthymics is developing a novel medicine for major depressive disorder. Euthymics’ management team is a group of experienced drug developers with a track record of success in neuroscience product development. We are dedicated to providing better medicines to patients with depression and alcohol use disorder.